Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pracytarabine vs Regorafenib in Advanced HCC
NCT07300488Phase 3Active, not recruiting
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pracytarabine in hepatocellular carcinoma (HCC), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd.. Started Sep 2025; status: active, not recruiting.
02
Drugs
pracytarabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07300488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300488.